Presentation by Yuko Ogata, Just – Evotec Biologics: Automated MAM Sample Preparation
Presentation by Yuko Ogata, Just – Evotec Biologics: Automated MAM Sample Preparation
Loading view.
CASSS MS Conference
CASSS MS Conference
Presentation by Lucie Manache-Alberici & Cedric Mesmin, Merck Group: Validation of an LC-MS Multi-Attribute Method (MAM) Supporting Biopharma Process Characterization.
Presentation by Lucie Manache-Alberici & Cedric Mesmin, Merck Group: Validation of an LC-MS Multi-Attribute Method (MAM) Supporting Biopharma Process Characterization.
Presentation by Shawn Li, Merck: Transition of Multi-Attribute Method (MAM) to GMP for biotherapeutics
Presentation by Shawn Li, Merck: Transition of Multi-Attribute Method (MAM) to GMP for biotherapeutics
Presentation by Yuting Huang, Pfizer: Accelerating Biotherapeutic Development by Automated MAM
Presentation by Yuting Huang, Pfizer: Accelerating Biotherapeutic Development by Automated MAM
Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
USP Biologics Open Forum on MAM
USP Biologics Open Forum on MAM
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the benefits of New Peak Detection
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the…
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes